When a prior-authorization request is denied, the patient faces an immediate access gap. The prescriber may appeal, but appeals take days to weeks. For specialty drugs treating chronic or progressive conditions — rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, oncology indications — a treatment gap of even two weeks can mean disease flare, irreversible damage, or an emergency-room visit.
Manufacturer bridge programs fill that gap by providing a limited supply of free drug while the appeal is resolved. The clinical logic is clear. The compliance boundary is not. Bridge programs exist in a zone where the federal Anti-Kickback Statute (AKS), the Civil Monetary Penalties (CMP) law on beneficiary inducements, and OIG enforcement guidance intersect. A poorly structured bridge program can look to a regulator like a manufacturer paying patients to stay on a branded drug instead of switching to a covered alternative.
This article is for hub leads, patient-support program managers, and compliance teams who need to understand where the lines are drawn and how to stay on the right side of them.
What a Bridge Program Actually Is
A bridge program is a manufacturer-sponsored, time-limited provision of free drug to a patient who has been prescribed the manufacturer's product but cannot access it due to a coverage barrier — most commonly a prior-authorization denial or a formulary exclusion. The program is distinct from:
- Patient assistance programs (PAPs), which provide ongoing free or subsidized drug to financially eligible patients, often uninsured or underinsured, typically run through independent charitable foundations or directly by the manufacturer.
- Copay assistance programs, which offset patient cost-sharing for commercially insured patients and are governed by copay accumulator/maximizer rules and state restrictions.
- Transition-of-care supplies, which Part D plans are required to provide when a beneficiary changes plans or encounters a new utilization-management edit, as described in CMS Chapter 6 guidance on transition policies.
A bridge program is specifically a short-term, appeal-pending intervention. The patient has coverage, the drug was prescribed, the payer said no, and the manufacturer provides temporary free drug while the prescriber navigates the appeals process.
The Compliance Framework
The Anti-Kickback Statute
The federal AKS (42 U.S.C. § 1320a-7b(b)) prohibits knowingly and willfully offering or paying remuneration to induce someone to purchase or order an item or service payable by a federal healthcare program. Free drug provided to a Medicare or Medicaid beneficiary is remuneration. The question is whether that remuneration is intended to induce the beneficiary to stay on the drug rather than switch to a covered alternative.
OIG has not issued a safe harbor specifically for manufacturer bridge programs. The program must be evaluated under the general AKS framework and relevant OIG advisory opinions.
OIG Advisory Opinions on Free Drug
OIG Advisory Opinion 25-01, issued in 2025, addressed a manufacturer's free-drug program for patients with financial need receiving an intravenous drug. OIG concluded it would not impose sanctions, citing several safeguards:
- Objective, financial-need-based eligibility criteria
- The drug was provided at no cost with no cost-sharing
- The program was not conditioned on the use of any specific provider, pharmacy, or supplier
- The manufacturer did not market or advertise the program in a way that would steer patients to the drug
The Mintz analysis of free drug programs distinguishes between manufacturer support programs — including bridge programs and direct subsidies — and charitable PAPs. Manufacturer support programs "take a variety of forms (e.g., bridge program, direct subsidy)" and their "eligibility requirements vary." The key compliance principle across all forms: the program must not be structured or operated as an inducement to select the manufacturer's product over alternatives.
The Beneficiary Inducements CMP
The CMP provision at 42 U.S.C. § 1320a-7a(a)(5) prohibits offering remuneration to a Medicare or Medicaid beneficiary that the offeror knows or should know is likely to influence the beneficiary's selection of a provider, practitioner, or supplier. This is a lower standard than the AKS — it does not require specific intent to induce. OIG clarified in Advisory Opinion 21-01 that the CMP Law can apply to pharmaceutical manufacturers if the manufacturer offers remuneration likely to influence a patient's selection of a particular provider, practitioner, or supplier. However, for bridge programs providing free drug directly to patients, the remuneration is more likely to influence drug selection than provider selection, making the AKS the more directly applicable statute.
Structural Safeguards for a Compliant Bridge Program
Based on OIG advisory opinions, the 2005 OIG Special Advisory Bulletin on patient assistance programs, and the 2026 OIG Special Advisory Bulletin on direct-to-consumer programs, the following structural elements reduce AKS risk for bridge programs:
1. Tie the Bridge to a Specific Appeal
The bridge should only be available when there is an active, documented appeal of a coverage denial. The patient's prescriber must have submitted a formal appeal or exception request, and the bridge program should verify this before dispensing. This distinguishes the bridge from a general free-drug program that could be seen as an inducement to start or continue the drug.
2. Limit Duration
A bridge program should provide drug for a defined, short period — typically 30 days or the expected duration of the standard appeal cycle, whichever is shorter. Reed Smith's analysis of OIG Advisory Opinion on drug assistance programs notes that "OIG specifically noted the limited timeframe during which the Refund Program was available. This could have potential implications for patient bridge programs or other patient assistance programs." Time-limited programs are viewed more favorably because they reduce the inference that the manufacturer is providing ongoing remuneration to retain the patient.
3. Use Objective Eligibility Criteria
Eligibility should be based on objective, verifiable criteria: the patient has a valid prescription, the drug is covered under the patient's plan but requires PA that was denied, and an appeal has been filed. Do not condition the bridge on the patient's willingness to continue with the drug indefinitely, to switch pharmacies, or to use a specific specialty pharmacy.
4. Separate Commercial Functions
The team administering the bridge program should be functionally separate from sales and marketing. The patient should not be enrolled in the bridge program through a sales representative. Morgan Lewis's review of OIG advisory opinions on PAPs emphasizes that programs are viewed more favorably when they are "widely available on direct-to-consumer basis" rather than targeted by sales teams.
5. Screen for Federal Program Beneficiaries
Bridge programs for commercially insured patients carry lower AKS risk because the AKS generally does not apply to transactions involving only commercial insurance. For Medicare and Medicaid beneficiaries, the AKS applies. The OIG's January 2026 Special Advisory Bulletin on DTC programs reiterates the foundational principle: if the drug provided through the program is not billed to a federal healthcare program, the AKS risk is reduced. Bridge programs should ensure that the free drug provided during the appeal is not billed to Medicare, Medicaid, or any federal program.
6. Document Everything
Each bridge enrollment should document: the date of PA denial, the date of appeal filing, the expected appeal timeline, the quantity of drug provided, and the disposition of the appeal. If the appeal is denied and the payer does not cover the drug, the patient should be transitioned to a longer-term PAP (if eligible) or informed of alternative therapies — not kept on an indefinite bridge.
Transition Risk: When the Bridge Ends
The most operationally dangerous moment in a bridge program is the transition out of it. There are three possible outcomes:
Appeal Granted
The payer covers the drug. The patient transitions from bridge supply to normal pharmacy fulfillment. This is the intended path. The hub team should have a workflow to confirm coverage is active before the bridge supply runs out, so the patient does not experience a gap.
Appeal Denied, Alternative Available
The payer denies the drug but covers a therapeutic alternative. The patient must transition to the alternative. The bridge program should not be used to keep the patient on the denied drug beyond the appeal period. Doing so creates the inference that the bridge is an inducement to avoid switching, which is precisely the AKS concern.
This is where hub teams face real operational pressure. The patient may prefer the originally prescribed drug. The prescriber may believe the denied drug is clinically superior. But from a compliance standpoint, the bridge has served its purpose — providing access during the appeal — and continuing free drug after a final denial shifts the program from a temporary bridge to a long-term free-drug arrangement that lacks a safe harbor.
Appeal Denied, No Covered Alternative
The payer denies the drug and no covered alternative exists. The patient should be evaluated for enrollment in the manufacturer's longer-term PAP or referred to an independent charitable foundation. The bridge should not become a de facto ongoing supply program. If the manufacturer's PAP has income-eligibility requirements, the patient must meet those independently of the bridge.
Interaction with CMS Transition-of-Care Requirements
Part D sponsors have their own transition obligations. CMS guidance requires plans to provide a transition supply — typically a 30-day supply — when a beneficiary encounters a utilization-management edit at point of sale, including prior-authorization requirements for new starts. The plan's transition policy overrides the PA edit at the pharmacy counter to allow a one-time supply.
This means the manufacturer's bridge program may not even be necessary for Medicare Part D patients in the initial denial period. The plan's own transition supply covers the first 30 days. The manufacturer bridge becomes relevant when the plan's transition supply is exhausted and the appeal is still pending.
Hub teams should verify whether a patient received a plan transition supply before enrolling them in a manufacturer bridge. Providing a bridge on top of a plan transition supply means the patient receives 60+ days of free drug — a duration that begins to look less like a bridge and more like an ongoing inducement.
State-Level Considerations
Several states have enacted laws restricting prior-authorization practices and, in some cases, imposing requirements on manufacturer assistance programs. The Mintz PBM policy update for Spring 2026 tracks state legislation: Oklahoma's H.B. 1808 (effective November 2025) creates the Ensuring Transparency in Prescription Drugs Prior Authorization Act, requiring utilization review entities to make PA requirements publicly accessible, setting timeframes for PA determinations, and limiting PA renewals for chronic-condition drugs to once every three years. These state-level PA reforms may reduce the duration of the appeal window, which in turn should shorten the necessary bridge period.
Some states restrict copay accumulator programs and, by extension, the interaction between manufacturer copay assistance and patient cost-sharing. While bridge programs are distinct from copay assistance, the regulatory environment around manufacturer-funded patient support is converging, and hub teams should track state laws in all markets where their bridge program operates.
The 2026 OIG DTC Bulletin and Its Implications
The January 2026 OIG Special Advisory Bulletin on direct-to-consumer programs was specific to manufacturer DTC sales to cash-paying patients. It does not directly address bridge programs. However, the Bulletin's framework is informative. OIG identified characteristics that minimize AKS risk: the drug is not billed to a federal program, the sale is not conditioned on other purchases, and the arrangement is structured to avoid steering. These principles map directly onto bridge program design.
Arnold & Porter's analysis of the DTC Bulletin notes that OIG "highlighted the following safeguards as important to reducing AKS risk: Independent Prescribing; No Federal Health Care Program Claims." For bridge programs, the analogous safeguards are: the bridge follows an independent prescribing decision (not a manufacturer-driven recommendation), the free drug is not billed to any federal program, and the bridge duration is limited to the appeal window.
Practical Checklist for Hub Teams
- Before enrollment: Verify active PA denial and appeal filing. Confirm the patient has not already received a plan transition supply that covers the bridge period.
- Eligibility screening: Use objective criteria only — valid prescription, PA denial, appeal filed, drug is on the patient's plan formulary but requires PA.
- Duration: Cap at 30 days or the expected appeal timeline, whichever is shorter. Do not renew without re-verifying appeal status.
- Separation of functions: Do not allow sales representatives to enroll patients. Use a dedicated patient-support team with compliance oversight.
- Federal program screening: For Medicare and Medicaid beneficiaries, ensure the free drug is not billed to any federal program. Document that the bridge supply was provided at no cost and no claim was submitted.
- Transition plan: Before the bridge ends, confirm the appeal outcome. If the appeal is granted, coordinate with the specialty pharmacy for normal fulfillment. If denied, transition the patient to PAP evaluation or inform the prescriber of alternatives.
- Documentation: Maintain records of PA denial, appeal filing, bridge enrollment, quantity dispensed, and appeal outcome for each patient.
Sources
- OIG Advisory Opinion 25-01. HHS Office of Inspector General, 2025. https://oig.hhs.gov
- OIG Advisory Opinion 21-01. HHS Office of Inspector General, 2021. https://oig.hhs.gov/compliance/advisory-opinions/21-01
- OIG Special Advisory Bulletin: Application of the Federal Anti-Kickback Statute to Direct-to-Consumer Prescription Drug Sales by Manufacturers to Patients With Federal Health Care Program Coverage. January 27, 2026. https://oig.hhs.gov
- OIG Safe Harbor Regulations. 42 C.F.R. § 1001.952. https://oig.hhs.gov/compliance/safe-harbor-regulations
- Morgan Lewis. Patient Assistance Programs — The Dos and Don'ts from HHS OIG. 2025. https://www.morganlewis.com/blogs/asprescribed/2025/02/patient-assistance-programs-the-dos-and-donts-from-hhs-oig
- Barnes & Thornburg. HHS OIG Highlights Anti-Fraud Safeguards of Drug Manufacturer's Free Drug Program for Patients in Financial Need. March 2025. https://btlaw.com/en/insights/alerts/2025/hhs-oig-highlights-anti-fraud-safeguards-of-drug-manufacturers-free-program-patients-financial-need
- Reed Smith. OIG Issues Favorable Opinion on Drug Assistance Programs. https://www.reedsmith.com/our-insights/blogs/health-industry-washington-watch/102k21b/oig-issues-favorable-opinion-on-drug-assistance-programs
- CMS. Medicare Part D Transition Policies. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
- Mintz. Free Drug Programs — Regulatory Guidance and Enforcement. https://www.mintz.com/sites/default/files/media/documents/2022-03-16/Document-Webinar_Slides-Pharma_Summit_2022-Free_Drug_Programs.pdf
- Mintz. PBM Policy and Legislative Update — Spring 2026. https://www.mintz.com/insights-center/viewpoints/2026-04-22-pbm-policy-and-legislative-update-spring-2026
- Arnold & Porter. HHS-OIG Guidance on Manufacturer DTC Platforms and Congressional Pushback. February 2026. https://www.arnoldporter.com/en/perspectives/advisories/2026/02/hhs-oig-guidance-on-manufacturer-dtc-platforms
- Dentons. HHS-OIG Issues Special Advisory Bulletin on Manufacturer Direct-to-Consumer Programs for Prescription Drugs. January 2026. https://www.dentonshealthlaw.com/hhs-oig-issues-special-advisory-bulletin-on-manufacturer-direct-to-consumer-programs-for-prescription-drugs
